Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adult population in western country. In the last decade, several findings have substantially revolutionized the old concept that CLL is a disease originating from mature, not-dividing cell with indolent clinical course. Notably, next generation sequencing (NGS) has contributed to deepen the knowledge of the cellular networks that imply the onset and the progression of CLL. Among genetic aberrations that are recurrently observed in B-cells from patients with CLL, microRNA deregulation represented the first epigenetic mechanism that has been identified. Through epigenetic mechanism they can modulate gene expression and interfere with cellular pathways that are involved in cell cycle, apoptosis and B-cell receptor (BCR) activation. Although few studies have shown the prognostic and predictive value of microRNA expression levels, their validation within prospective clinical trials is warranted.
Keywords: Chronic lymphocytic leukemia, del13q, del17p, microRNAs, miR-15, miR-16a.
Graphical Abstract
MicroRNA
Title:MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
Volume: 5 Issue: 2
Author(s): Maria Ciccone and George A. Calin
Affiliation:
Keywords: Chronic lymphocytic leukemia, del13q, del17p, microRNAs, miR-15, miR-16a.
Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia among adult population in western country. In the last decade, several findings have substantially revolutionized the old concept that CLL is a disease originating from mature, not-dividing cell with indolent clinical course. Notably, next generation sequencing (NGS) has contributed to deepen the knowledge of the cellular networks that imply the onset and the progression of CLL. Among genetic aberrations that are recurrently observed in B-cells from patients with CLL, microRNA deregulation represented the first epigenetic mechanism that has been identified. Through epigenetic mechanism they can modulate gene expression and interfere with cellular pathways that are involved in cell cycle, apoptosis and B-cell receptor (BCR) activation. Although few studies have shown the prognostic and predictive value of microRNA expression levels, their validation within prospective clinical trials is warranted.
Export Options
About this article
Cite this article as:
Ciccone Maria and Calin A. George, MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights, MicroRNA 2016; 5 (2) . https://dx.doi.org/10.2174/2211536605666160825150219
DOI https://dx.doi.org/10.2174/2211536605666160825150219 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Molecular Mechanisms Responsible for <i>In Vitro</i> Cytotoxic Attributes of <i>Conyza bonariensis</i> Extract against Lymphoblastic Leukaemia Jurkat Cells
Anti-Cancer Agents in Medicinal Chemistry CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Effects of Bioactive Compounds from Carrots (Daucus carota L.), Polyacetylenes, Beta-Carotene and Lutein on Human Lymphoid Leukaemia Cells
Anti-Cancer Agents in Medicinal Chemistry Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients
Cardiovascular & Hematological Disorders-Drug Targets Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Potential Health Benefits of Berries
Current Nutrition & Food Science PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design